Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer AND Docetaxel

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    723 result(s) found for: Cancer AND Docetaxel. Displaying page 17 of 37.
    «« First « Previous 13  14  15  16  17  18  19  20  21  Next» Last»»
    EudraCT Number: 2011-002007-15 Sponsor Protocol Number: AXL-003 Start Date*: 2011-10-12
    Sponsor Name:Axelar AB
    Full Title: Phase II, randomized, open-label study of the IGF-1R inhibitor AXL1717 compared to docetaxel in patients with previously treated, locally advanced, or metastatic squamous cell carcinoma or adenocar...
    Medical condition: Non-small-cell lung cancer previously treated
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-004847-47 Sponsor Protocol Number: DOCET_L_01704 Start Date*: 2007-06-12
    Sponsor Name:Jeroen Bosch - Groot Ziekengasthuis
    Full Title: A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLC
    Medical condition: patients with refractory or relapsed small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041067 Small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001720-37 Sponsor Protocol Number: CRO-2011-12 Start Date*: 2011-12-01
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
    Full Title: Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer
    Medical condition: patients with metastatic gastric carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000914-39 Sponsor Protocol Number: 2018-21 Start Date*: 2018-11-15
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018015-11 Sponsor Protocol Number: IMCLCP15-0805 Start Date*: 2010-10-20
    Sponsor Name:ImClone LLC
    Full Title: A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CR...
    Medical condition: Metastatic Castration-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-002738-36 Sponsor Protocol Number: G-0029 Start Date*: 2005-11-08
    Sponsor Name:Cell Genesys Inc
    Full Title: A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10036909
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001904-10 Sponsor Protocol Number: PM0259CA301J1 Start Date*: 2004-09-15
    Sponsor Name:Pierre Fabre Médicament represented by IRPF
    Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ...
    Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003656-40 Sponsor Protocol Number: PCYC-1128-CA Start Date*: 2016-02-17
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
    Medical condition: Metastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-003520-37 Sponsor Protocol Number: D081DC00008 Start Date*: 2014-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatmen...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) CZ (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004377-13 Sponsor Protocol Number: CA209-9HX Start Date*: 2018-11-21
    Sponsor Name:SOGUG (Spanish Genitourinary Oncologic Group)
    Full Title: A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer.
    Medical condition: metastatic hormone-sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001825-32 Sponsor Protocol Number: TTD-08-02 Start Date*: 2008-07-01
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: "Fase II Docetaxel-Oxiplatino-Capecitabina (DOX) a dosis ajustadas en pacientes con adenocarcinoma gástrico avanzado y estado general subóptimo"
    Medical condition: Pacientes diagnosticados histológicamente de adenocarcinoma gástrico o de la unión esófago gástrica (tipos I, II y III de Siewert) localmente avanzado irresecable, metastásico o recidivado.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002323-25 Sponsor Protocol Number: FBCG-01-2015 Start Date*: 2015-06-25
    Sponsor Name:Finnish Breast Cancer Group
    Full Title: A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive bre...
    Medical condition: Early HER-2 -positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004332-36 Sponsor Protocol Number: DTX-SPL8783-002 Start Date*: 2020-02-01
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients wit...
    Medical condition: Advanced malignant solid tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000262-38 Sponsor Protocol Number: CA209-77T Start Date*: 2019-08-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolum...
    Medical condition: Resectable Stage II-IIIB Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005728-17 Sponsor Protocol Number: HOP LITE Start Date*: 2006-11-02
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine.
    Medical condition: Prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036909 PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000752-17 Sponsor Protocol Number: WO17299 Start Date*: 2004-08-24
    Sponsor Name:Hoffmann-La Roche Ltd/Inc/AG/Roche Global Development
    Full Title: Phase II study of Herceptin® alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin® in the adjuvan...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    10027475
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001179-60 Sponsor Protocol Number: CABASTY Start Date*: 2019-10-21
    Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)
    Full Title: Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with metastatic castration-resi...
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease:
    Population Age: Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002997-72 Sponsor Protocol Number: TOC4129g/WO20698 Start Date*: 2008-02-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOU...
    Medical condition: HER2 positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Completed) GB (Completed) ES (Completed) FR (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-009315-22 Sponsor Protocol Number: NVALT10 Start Date*: 2009-02-25
    Sponsor Name:NVALT
    Full Title: A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study)
    Medical condition: patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003332-29 Sponsor Protocol Number: ICORG 06-05 Start Date*: 2007-03-30
    Sponsor Name:ICORG, all-Ireland Cooperative Oncology Research Group
    Full Title: A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial
    Medical condition: Advanced Gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062878 Gastrooesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 13  14  15  16  17  18  19  20  21  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 15:05:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA